Association Between ERCC2 Lys751Gln Polymorphism and Lung Cancer Risk: A Meta-Analysis Involving 23,370 Subjects

Tan, Xiang; Xian, Lei; Chen, Xinyu; Shi, Lijun; Wang, Yongyong; Guo, Jianji; Liang, Guanbiao; Zhao, Zhenqing; Chen, Mingwu

doi:10.1017/thg.2014.4

Cited by 10 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, so many meta-analysis had investigated the association between the gene polymorphisms and the risk of lung cancer. The meta-analysis of Tan et al [ 25 ] had reported a correlation between (ERCC2) Lys751Gln polymorphism and an increased risk of lung cancer based on 23,370 subjects. Wang et al [ 26 ] performed a meta-analysis showed that there was no association between IL-6 rs1800796 polymorphism and lung cancer, etc.…”

Section: Discussionmentioning

confidence: 99%

Association between Catechol-O-methyltransferase rs4680 (G > A) polymorphism and lung cancer risk

Tan

Chen

2014

Diagn Pathol

Self Cite

View full text Add to dashboard Cite

BackgroundThe association between the Val158Met polymorphism in the catechol-O-methyltransferase (COMT) gene and lung cancer risk remains controversial and inconclusive. Therefore, the meta-analysis was performed to provide a quality reevaluation of the association between the COMT Val158Met polymorphism and the risk of lung cancer.MethodsTwo major public databases (Pubmed and Embase) and several Chinese databases were searched for eligible studies. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated to estimate the strength of the association.ResultsFive publications, including six individual studies with a total of 4,043 subjects (1,796 cases and 2,247 controls) regarding the association of COMT Val158Met polymorphism with lung cancer susceptibility were included in this meta-analysis. Overall, pooled analysis indicated that there was no significant association between COMT Val158Met polymorphism and lung cancer susceptibility under all genetic models. Likewise, no association was observed in the stratified analysis by ethnicity and control source, either. However, Val158Met polymorphism was shown to increase lung cancer risk among women (AG vs. GG, OR = 1.190, 95% CI = 1.001–1.422, p = 0.049).ConclusionThese findings suggested that the COMT l58Val/Met polymorphism confer genetic susceptibility to lung cancer among women. However, no evidence was found for the association with lung cancer risk in ethnicity and smoking status.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_192

show abstract

Section: Discussionmentioning

confidence: 99%

Association between Catechol-O-methyltransferase rs4680 (G > A) polymorphism and lung cancer risk

Tan

Chen

2014

Diagn Pathol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Heterogeneity across studies was tested by a chi-square-based Q test (heterogeneity was considered to exist between studies when p < .10 and I 2 > 25% for the Q test, with 25% < I 2 < 50% regarded as low heterogeneity, 50% ≤ I 2 ≤ 75% regarded as moderate heterogeneity, and I 2 > 75% as high heterogeneity). We calculated pooled ORs with a fixed-effects model if there was no heterogeneity; where the p value was <.10, a random-effect model was adopted (Tan et al, 2014). If heterogeneity was observed, meta-regression analyses would be performed to explore the potential source of the heterogeneity (Higgins & Thompson 2004; Thompson & Higgins, 2002).…”

Section: Methodsmentioning

confidence: 99%

Polymorphism of HSD17B1 Ser312Gly with Cancer Risk: Evidence from 66,147 Subjects

et al. 2016

Self Cite

View full text Add to dashboard Cite

Hydroxysteroid (17-beta)dehydrogenase 1(HSD17B1) plays a central role in sex steroid hormone metabolism. HSD17B1 polymorphic variants may contribute to cancer susceptibility. Numerous investigations have been conducted to assess the association between HSD17B1 Ser312Gly polymorphism and cancer risk in multiple ethnicities, yet these have produced inconsistent results. We therefore performed this comprehensive meta-analysis to attempt to provide a quality assessment of the association of interest. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of associations. After a systematic literature search of several major public databases, 20 studies involving 29,460 cases and 36,687 controls were included in this meta-analysis. No significant association was found between HSD17B1 Ser312Gly polymorphism and cancer risk. However, Ser312Gly polymorphism showed a significantly decreased risk for Caucasians (there were 44,284 Caucasians for analysis, comprising 19,889 cases and 24,395 controls) in the subgroup analysis by ethnicity (dominant: OR = 0.958, 95% CI = 0.919-0.998; and allele comparing: OR = 0.973, 95% CI = 0.947-0.999). And there was the same trend towards risk in the population-based (PB) controls (homozygous: OR = 0.951, 95% CI = 0.908-0.997 and allele comparing: OR = 0.976, 95% CI = 0.954-0.999), but not among Asians or hospital-based (HB) controls. In addition, no association was observed in the stratified analysis for breast cancer studies by source of control, ethnicity and quality score. These findings suggested that the HSD17B1 Ser312Gly polymorphism might confer genetic cancer susceptibility in an ethnic-dependent manner, especially among Caucasians. Well-designed, large-scale studies are warranted to validate these findings.

show abstract

“…Many epidemiological studies with the aim of identifying the role of ERCC2 polymorphisms in the risk of various cancers have been done and different association between Lys751Gln polymorphism and the risk of lung cancer [ 3 – 5 ], glioma [ 6 ], colorectal cancer [ 7 ], breast cancer [ 8 , 9 ], and esophageal squamous cell carcinoma [ 10 ] has been reported.…”

Section: Introductionmentioning

confidence: 99%

An Association between Single Nucleotide Polymorphisms of Lys751GlnERCC2Gene and Ovarian Cancer in Polish Women

Michalska

Samulak

Romanowicz

et al. 2015

Advances in Medicine

View full text Add to dashboard Cite

Aim. The aim of this study was to evaluate the role of the Lys751Gln (rs13181) ERCC2 gene polymorphism in clinical parameters and the risk for development of ovarian cancer. Material and Methods. The study consisted of 430 patients with ovarian cancer (mean age: 53.2 ± 10.11) and 430 healthy subjects (mean age: 50.31 ± 18.21). Analysis of the gene polymorphisms was performed using the PCR-based restriction fragment length polymorphism (PCR-RFLP). The odds ratios (ORs) and 95% confidence intervals (CIs) for each genotype and allele were calculated. Results. The results obtained indicate that the genotype Gln/Gln is associated with an increased risk of ovarian cancer (OR 5.01; 95% CI 3.37–7.43; p < 0.0001). Association of Lys751Gln polymorphism with histological grading showed increased ERCC2 Gln/Gln (OR = 6.96; 95% CI 3.41–14.21; p < 0.0001) genotype in grading 1 as well as Gln allele overrepresentation (OR = 4.98; 95% CI 3.37–7.40; p < 0.0001) in G1 ovarian patients. Finally, with clinical FIGO staging under evaluation, an increase in ERCC2 Gln/Gln homozygote frequencies in staging I and Gln allele frequencies in SI were observed. Conclusion. On the basis of these results, we conclude that ERCC2 gene polymorphism Lys751Gln may be associated with an increased risk of ovarian carcinoma.

show abstract

Association Between ERCC2 Lys751Gln Polymorphism and Lung Cancer Risk: A Meta-Analysis Involving 23,370 Subjects

Cited by 10 publications

References 51 publications

Association between Catechol-O-methyltransferase rs4680 (G > A) polymorphism and lung cancer risk

Association between Catechol-O-methyltransferase rs4680 (G > A) polymorphism and lung cancer risk

Polymorphism of HSD17B1 Ser312Gly with Cancer Risk: Evidence from 66,147 Subjects

An Association between Single Nucleotide Polymorphisms of Lys751GlnERCC2Gene and Ovarian Cancer in Polish Women

Contact Info

Product

Resources

About